• image06

    The bottom Line is

    Excellence

  • image01

    The bottom Line is

    Depth

  • image02

    The bottom Line is

    Differentiation

  • image04

    The bottom Line is

    People

  • image03

    The bottom Line is

    Efficiency

  • image05

    The bottom Line is

    Happiness

Lupin Inks Strategic Joint Venture Agreement with Yoshindo Inc

Pharma Major, Lupin  Limited  (Lupin) announced  today  that  it has entered  into a  strategic  joint  venture  agreement  with  Toyama  based  Japanese  pharmaceuticals  company,  Yoshindo  Inc.  (Yoshindo)  to  create  a  new  entity,  YL  Biologics  (YLB).  YLB  will  be  jointly managed  by  both  partners  and  will  be  responsible  for  conducting  clinical  development of certain Biosimilars including regulatory filings and obtaining marketing authorizations in Japan.

Lupin Appoints Theresa Stevens as Chief Corporate Development Officer

Pharma major Lupin today announced the appointment of Theresa Stevens as Chief Corporate Development Officer for its global operations. Theresa will assume full responsibility for global merger and acquisitions and specialty business strategy. Prior to joining Lupin, Theresa was with Aptalis pharma as the Chief Corporate Development Officer responsible for Mergers & Acquisitions (M&A), Strategy and Global Business Development.

Lupin Receives FDA Approval for Generic Actos® Tablets

Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Pioglitazone Tablets USP, 15 mg, 30 mg, and 45 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Takeda Pharmaceuticals USA, Inc.’s (Takeda) Actos® Tablets, 15 mg, 30 mg, and 45 mg. Lupin Pharmaceuticals Inc. (LPI), the company’s US subsidiary would commence marketing the product shortly.

Lupin Acquires Laboratorios Grin S.A. De C.V., Mexico; Specialty Ophthalmic Company; Enters the Latin American Market

Pharma Major Lupin Limited announced today the acquisition of 100 % equity stake in Laboratorios Grin, S.A. De C.V. (Grin), Mexico, subject to certain closing conditions. The acquisition marks Lupin’s foray into the high growth Mexican and the larger Latin American pharmaceuticals market. Mexico is one of the fastest growing pharmaceutical markets in the world valued at over USD 13.5 billion and growing at 9- 10% annually.

Lupin launches Generic Niaspan® Tablets in the US

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) yesterday.

Lupin Receives FDA Approval for Generic Monodox® Capsules and Cipro® for Oral Suspension

Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Aqua Pharmaceuticals Monodox® Capsules 50 mg, 75 mg, and 100 mg.

Stock Price

FINANCIALS SNAPSHOT

Standing on the shoulders of sustained growth in the past, we have delivered the best growth numbers in the Industry for the last 6 years.

Read more
MEDIA CENTER

Lupin launches Generic Geodon® Capsules Receives final FDA Approval for its Generic Geodon® Capsules.

Read more
THE LUPIN STORY

The company was named after the Lupin flower because of the inherent qualities of the flower.

Read more

OUR GLOBAL WEBSITES

USA
Japan (Kyowa) JAPAN (I’rom)
South Africa
Australia
Philippines
Germany
NETHERLANDS
MEXICO